PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114)

Gustavo Werutsky¹, Bruno Hochhegger², José Antônio Lopes de Figueiredo Pinto², Jeovany Martínez-Mesa³, Mara Lise Zanini⁴, Eduardo Herz Berdichevski⁴, Eduardo Vilas⁴, Vinicius Duval da Silva⁵, Maria Teresa Ruiz Tsukazan⁵, Arthur Vieira⁵, Leandro Genehr Fritscher², Louise Hartmann⁴, Marcos Alba⁴, Guilherme Sartori¹, Cristina Matushita⁴, Vanessa Bortolotto¹, Rayssa Ruszkowski do Amaral¹, Luís Carlos Anflor Junior⁵, Facundo Zaffaroni¹, Carlos H. Barrios¹, Márcio Debiasi¹ and Carlos Cezar Frietscher²

Abstract

Background: The present study aims to assess the performance of 18F-FDG PET-CT on mediastinal staging of non-small cell lung cancer (NSCLC) in a location with endemic granulomatous infectious disease.

Methods: Diagnostic test study including patients aged 18 years or older with operable stage I-III NSCLC and indication for a mediastinal lymph node biopsy. All patients underwent a 18F-FDG PET-scan before invasive mediastinal staging, either through mediastinoscopy or thoracotomy, which was considered the gold-standard. Surgeons and pathologists were blinded for scan results. Primary endpoint was to evaluate sensitivity, specificity and positive and negative predictive values of PET-CT with images acquired in the 1st hour of the exam protocol, using predefined cutoffs of maximal SUV, on per-patient basis.

Results: Overall, 85 patients with operable NSCLC underwent PET-CT scan followed by invasive mediastinal staging. Mean age was 65 years, 49 patients were male and 68 were white. One patient presented with active tuberculosis and none had HIV infection. Using any SUV_max > 0 as qualitative criteria for positivity, sensitivity and specificity were 0.87 and 0.45, respectively. Nevertheless, even when the highest SUV cut-off was used (SUV_max ≥ 5), specificity remained low (0.79), with an estimated positive predictive value of 54%.

Conclusions: Our findings are in line with the most recent publications and guidelines, which recommend that PET-CT must not be solely used as a tool to mediastinal staging, even in a region with high burden of tuberculosis.

Trial registration: The LACOG 0114 study was registered at ClinicalTrials.gov, before study initiation, under identifier NCT02664792.

Keywords: Non-small cell lung cancer, PET-CT, Mediastinal staging, Granulomatous infectious diseases

* Correspondence: gustavo.werutsky@lacog.org.br
¹Latin American Cooperative Oncology Group (LACOG), Ipiranga Avenue 6681, 99A, Room 805, Porto Alegre, Brazil
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Lung cancer is the leading cause of cancer-related death in the world. It is responsible for 1,350,000 new cases and 1,180,000 deaths annually worldwide [1]. In Brazil, the incidence of lung cancer is also rising, accounting for approximately 28,000 new cases and 24,500 deaths yearly, according to the most recent report from INCA, the Brazilian National Institute of Cancer [2].

Despite recent advances in terms of early diagnosis achieved with low-dose Computed Tomography (CT) screening, most cases of lung cancer are still diagnosed at late clinical stages (CS), IIIb or IV. In Brazil, approximately 70% of patients present with locally advanced or metastatic disease [3]. Accurate staging of patients with non-small-cell lung cancer (NSCLC) is critical for defining the best treatment modality and predicting prognosis [4]. In the absence of distant metastasis, the status of mediastinal lymph nodes plays a critical role for treatment decisions. In this clinical scenario, the identification of positive mediastinal nodes changes the treatment option from surgery to multimodality treatment approach [5].

Since 2003, PET scan (Positron Emission Tomography) with 18F-fluorodeoxyglucose (18F-FDG) is recommended for NSCLC staging due to its high sensitivity to detect cancer [6, 7]. Currently, PET-CT is the gold-standard procedure for the non-invasive staging of NSCLC patients because it has the capability of identifying distant metastasis that would pass unnoticed in CT, preventing over 30% of unnecessary thoracotomies [8].

Invasive staging of the mediastinal nodes with mediastinoscopy is still the standard of care and the value of PET-CT for this indication is debatable. Previous studies showed sensitivity ranging from 77 to 90% and specificity of 86% for PET-CT in detecting the spread of NSCLC to the mediastinal lymph nodes [9]. One of the most important problems with the use of PET-CT in this situation are the false positives findings. It occurs because 18F-FDG is not a tumor specific agent and other conditions such as granulomatous diseases might present with a high 18F-FDG uptake [10–12].

The aim of this study is to validate PET-CT performance on mediastinal staging of patients with NSCLC living in an endemic area of tuberculosis.

Methods
Trial design
The present study is a diagnostic test study designed to evaluate PET-CT performance on the diagnosis of metastatic mediastinal lymph nodes compared with the gold-standard invasive staging with biopsy in patients with non-small cell lung carcinoma.

Patients
Patients were recruited from the department of Thoracic Surgery at Hospital São Lucas, a tertiary hospital supported by the Public Health System in southern Brazil. Patients aged 18 years or older were eligible if they had newly diagnosed or highly suspected NSCLC and indication for mediastinal lymph node biopsy based on current practice guidelines for staging. All patients were considered to have operable stage I-III disease after initial evaluation (medical history, physical examination and contrast-enhanced CT scan of the chest and upper abdomen). Exclusion criteria were any prior treatment for NSCLC (surgery, chemotherapy or radiotherapy), confirmed distant metastases, pregnancy (women in childbearing age had to agree to taking contraceptive measures and present a negative pregnancy test), altered hematologic and biochemical function.

Procedures
Patients included in the study were first subjected to a PET-CT scan, which were obtained using integrated PET-CT system (GE Discovery 600) as follows: after a 6-h fast, 18F-FDG was given intravenously with activity of 10 to 15 mCi. Images were acquired 1 and 2 h after the administration of 18F-FDG. Patients were scanned from the head to the upper thigh. A diagnostic CT scan, obtained with the use of a standard protocol (80 to 100 mA, 120 kV, a tube-rotation time of 0.5 s per rotation, a pitch of 6, and a slice thickness of 5 mm, with 70 ml of intravenous contrast medium containing 300 mg of iodine per milliliter [Ultravist, Bayer Schering], administered at a rate of 2.5 ml per second), preceded the PET scan (a 5-min emission scan per table position and 25 min total). The PET scan was reconstructed by filtered back-projection and ordered-subset expectation-maximization (OS-EM), with data from the CT scan used for attenuation correction. Results were evaluated by a radiologist and a nuclear medicine specialist. The maximum standardized uptake value (SUV_max) of the primary tumor was measured and calculated by the software according to standard formulas. Mediastinal lymph node stations were considered positive for metastatic spread if they exhibited focally increased FDG uptake higher than the normal background activity (activity > background), as determined by qualitative analysis. After the PET-CT scan, invasive mediastinal staging was performed. Mediastinoscopy or thoracotomy were considered valid invasive mediastinal staging procedures and were chosen according to surgeon’s discretion. The surgical team was blinded to PET-CT’s results.

Statistical analysis
The finding of mediastinal lymph nodes with increased 18F-FDG uptake on PET/CT was compared with pathological examination of lymph nodes obtained in the
invasive staging procedure. The study primary endpoint was to evaluate PET-CT’s performance with images acquired in the 1st hour of the exam protocol in a per-patient basis. The secondary endpoints were determining PET-CT performance in the 2nd hour of the exam protocol, and evaluate PET-CT’s performance in the 1st hour of the exam protocol evaluated per-nodal station basis (2R, 2L, 4R, 4L and 7). Categorical variables were described as their count and percentage. Numerical variables were described as their median, minimum and maximum. Sensitivities, specificities and predictive values were calculated using predefined cut-offs of maximal SUV. The 95% confidence intervals were calculated for sensitivity, specificity and predictive values. A receiver-operating-characteristic (ROC) analysis was performed on the PET-CT per-patient results. In order to obtain a minimal sensitivity and specificity of 90%, while expecting a 40% rate of positive lymph nodes, we estimated that 89 patients would be needed accepting a two-sided type I error of 5%. Assuming a 10% ineligibility rate, the total sample size was 100 patients. Statistical analysis was performed with the use of SPSS software, version 18, and SAS software, version 9.4.

Results
Baseline characteristics
From August 2014 to August 2016, 108 patients were enrolled in the study. Eight patients did not perform the PET-CT scan. Of the remaining 100 patients, 85 underwent mediastinal sampling biopsy (by mediastinoscopy or surgery) after PETCT and they were considered for primary analysis. The STARD flow diagram is shown in Fig. 1.

Table 1 shows baseline characteristics of eligible patients who performed mediastinal sampling. Median age was 65 years, 57.6% patients were male and 80.0% were white. Current or former smokers accounted for 94.1% of the sample, with a high tobacco exposure (median of 45 pack-years). Although the relatively high incidence of tuberculosis in Brazil, only one patient had known TB infection and no patient had an HIV infection.
Comparison of PET-CT and mediastinal invasive staging

From 85 patients, only 23 patients (27.1%) had pathological mediastinal involvement. Of these, PET-CT correctly identified 20 patients (86.9%) that showed an increased uptake of 18F-FDG. Conversely, PET-CT showed increased uptake in the mediastinum of 34 patients that were later on not confirmed to have pathological mediastinal involvement (false-positive rate of 54.8%). 28 out of 62 patients who did not have lymph node involvement on histological analysis did not have increased uptake on PET CT (true-negative rate of 45.2%). When a higher cut-off was used (SUV max \( \geq 5 \)), the false-positive rate reduced to 21.0% and the true-negative rate increased to 79.0%. For the same SUV cut-offs, we found an increased FDG uptake in hour 2, although this difference may not be clinically relevant.

When evaluated the 212 available nodal stations, 38 of them had pathological mediastinal involvement (17.9%). Of those 38, PET-CT correctly identified 25 of them (65.8%). 128 out of 174 lymph nodes who did not have involvement on histological analysis did not have increased uptake on PET CT (true-negative rate of 73.6%). Considering SUV max \( \geq 5 \), the true-positive rate decreased to 47.4% and the true-negative rate increased to 91.4% (Tables 2 and 3).

As showed in Table 3, the highest sensitivity (87%) was observed for the SUV_max > 0 cut-off. The negative predictive value (NPV) using this cut-off was 90%, which wasn’t changed for the images acquired in hour 2. By contrast, in the scenario with the highest specificity, when only uptake with SUV \( \geq 5 \) was considered positive, we found a positive predictive value of only 54%. When

---

**Table 1** Patient’s characteristics at baseline

| Characteristic               | N (%) or median (min-max) (n = 85) |
|------------------------------|-----------------------------------|
| Age (years)                  | 65.0 (47.0–80.0)                  |
| Sex                          |                                   |
| Male                         | 49 (57.6%)                        |
| Female                       | 36 (42.4%)                        |
| Race                         |                                   |
| White                        | 68 (80.0%)                        |
| Black                        | 7 (8.2%)                          |
| Other                        | 10 (11.8%)                        |
| Smoking status               |                                   |
| Current                      | 35 (41.2%)                        |
| Former                       | 45 (52.9%)                        |
| Never                        | 5 (5.9%)                          |
| Tobacco Exposure (Pack-year)* | 45.0 (8.1–120.0)                  |
| Comorbidities                |                                   |
| Hypertension                 | 40 (47.1%)                        |
| Diabetes                     | 11 (12.9%)                        |
| COPD                         | 30 (35.3%)                        |
| Asthma                       | 9 (10.6%)                         |
| Active Tuberculosis          | 1 (1.2%)                          |
| HIV positive                 | 0 (0.0%)                          |

Data is presented here as mean (minimum-maximum) or absolute (relative) frequencies. *This analysis takes into account only the 79 patients that were smokers or former smokers.

**Table 2** PET-CT findings and pathological evaluation of mediastinal lymph nodes after surgical staging (per-patient and per-nodal-station)

| PET-CT SUV cut-off | Pathological evaluation of mediastinal lymph nodes | PER-PATIENT (n = 85) | PER-NODAL-STATION (n = 212) |
|-------------------|---------------------------------------------------|----------------------|----------------------------|
|                   |                                                   | HOUR 1 | HOUR 2 | HOUR 1 | HOUR 2 |
| Positive          |                                                   | Positive | Negative | Positive | Negative |
| Negative          |                                                   | 20 | 3 | 20 | 3 | 25 | 13 |
| Positive          |                                                   | 34 | 28 | 35 | 27 | 46 | 128 |
| Negative          |                                                   | 18 | 5 | 19 | 4 | 23 | 15 |
| Positive          |                                                   | 30 | 32 | 30 | 32 | 40 | 134 |
| Negative          |                                                   | 16 | 7 | 18 | 5 | 21 | 17 |
| Positive          |                                                   | 24 | 38 | 26 | 36 | 32 | 142 |
| Negative          |                                                   | 15 | 8 | 16 | 7 | 18 | 20 |
| Positive          |                                                   | 13 | 49 | 18 | 44 | 15 | 159 |
| Negative          |                                                   | 18 | 5 | 18 | 4 | – | – |
| Positive          |                                                   | 23 | 37 | 25 | 34 | – | – |

*SUV Max: Maximum value of SUV uptake between 2R, 2L, 4R, 4 L, 7 and aortopulmonary when evaluating per-patient, and 2R, 2L, 2R, 4 L and 7 when evaluating per-nodal-station.
using the liver FDG uptake as cut-off for SUV positivity, the sensitivity and specificity was not improved

The image acquisition in hour 2 of the protocol did not change the accuracy of the test using ROC (Receiver Operator Characteristic) curve (Fig. 2).

Among 31 patients with no uptake in mediastinum (SUV = 0), 3 (9.6%) had metastatic lymph node involvement after mediastinal invasive staging (Fig. 3).

**Discussion**
Therapeutic options for patients with non-metastatic potentially resectable NSCLC are mainly determined by the presence or absence of mediastinal lymph node metastases (N2). While patients with resectable disease and no evidence of mediastinal lymph node involvement have surgery as the primary treatment, patients with N2 disease usually undergo a multimodality approach in order to maximize treatment outcomes.

Compared with cervical mediastinoscopy, PET-CT has the advantage of being a non-invasive staging method that is becoming increasingly available and has solid data regarding its accuracy. Nevertheless, the pivotal studies were undertaken in areas without endemic cases of tuberculosis and other infectious granulomatous disease [13, 14].

The role of PET-CT in mediastinal staging has been reviewed in a Cochrane meta-analysis [15], which included 18 studies that used 18F-FDG uptake higher than the background activity as qualitative criteria for PET-CT positivity. Sensitivity and specificity estimates were 77.4% (95% CI 65.3 to 86.1) and 90.1% (95% CI 85.3 to 93.5), respectively.

However, some clinicopathological factors have been associated with incorrect PET/CT staging. On multivariate analysis, Al Sarraf [16] showed that rheumatoid arthritis, non-insulin dependent diabetes, history of tuberculosis, presence of atypical adenomatous hyperplasia and pneumonia were independent factors causing inaccurate staging of mediastinal lymph nodes.

An important factor in countries with high burden of granulomatous infectious disease is the reduction of PET-CT reliability in this scenario [17, 18]. According to the World Health Organization (WHO), Brazil ranks as one of the top 20 countries in terms of tuberculosis incidence [19]. Particularly, Porto Alegre, the city where this study has taken place, has an incidence rate of 99.3 cases per 100,000 population [20].

Our report shows that no major impact in sensitivity is seen in an area endemic for tuberculosis and is similar to the literature [15]. On the other hand, specificity is

| Table 3 | Sensitivity and specificity of PET-CT using different maximum SUV cutoffs for the staging of the mediastinal lymph nodes (per-patient and per-nodal-station) |
|---------|--------------------------------------------------------------------------------------------------|
| Cut-off | Measure | Hour 1 (Per-Patient) | Hour 2 (Per-Patient) | Hour 1 (Per-Nodal-Station) |
| SUV\_Max\textsuperscript{a} > 0 | Sensitivity | 0.87 (0.66–0.97) | 0.87 (0.66–0.97) | 0.66 (0.49–0.80) |
| | Specificity | 0.45 (0.33–0.58) | 0.44 (0.31–0.57) | 0.74 (0.66–0.80) |
| | Positive Predictive Value | 0.37 (0.31–0.44) | 0.36 (0.30–0.43) | 0.35 (0.28–0.43) |
| | Negative Predictive Value | 0.90 (0.76–0.97) | 0.90 (0.75–0.96) | 0.91 (0.86–0.94) |
| SUV\_Max\textsuperscript{a} ≥ 2.5 | Sensitivity | 0.78 (0.56–0.93) | 0.83 (0.61–0.95) | 0.61 (0.43–0.76) |
| | Specificity | 0.52 (0.39–0.65) | 0.52 (0.39–0.65) | 0.77 (0.70–0.83) |
| | Positive Predictive Value | 0.38 (0.30–0.46) | 0.39 (0.32–0.47) | 0.37 (0.28–0.46) |
| | Negative Predictive Value | 0.87 (0.74–0.94) | 0.89 (0.76–0.95) | 0.90 (0.86–0.93) |
| SUV\_Max\textsuperscript{a} ≥ 3 | Sensitivity | 0.70 (0.47–0.87) | 0.78 (0.56–0.93) | 0.55 (0.38–0.71) |
| | Specificity | 0.61 (0.48–0.73) | 0.58 (0.45–0.71) | 0.82 (0.75–0.87) |
| | Positive Predictive Value | 0.40 (0.31–0.50) | 0.41 (0.33–0.50) | 0.40 (0.30–0.50) |
| | Negative Predictive Value | 0.84 (0.74–0.91) | 0.88 (0.76–0.94) | 0.89 (0.85–0.92) |
| SUV\_Max\textsuperscript{a} ≥ 5 | Sensitivity | 0.65 (0.43–0.84) | 0.70 (0.47–0.87) | 0.47 (0.31–0.64) |
| | Specificity | 0.79 (0.67–0.88) | 0.71 (0.58–0.82) | 0.91 (0.86–0.95) |
| | Positive Predictive Value | 0.54 (0.40–0.67) | 0.47 (0.36–0.59) | 0.55 (0.40–0.68) |
| | Negative Predictive Value | 0.86 (0.78–0.92) | 0.86 (0.77–0.92) | 0.89 (0.85–0.92) |
| SUV\_Max\textsuperscript{a} ≥ SUV\_Liver | Sensitivity | 0.78 (0.56–0.93) | 0.82 (0.60–0.95) | – |
| | Specificity | 0.62 (0.48–0.74) | 0.58 (0.44–0.70) | – |
| | Positive Predictive Value | 0.44 (0.35–0.54) | 0.42 (0.34–0.51) | – |
| | Negative Predictive Value | 0.88 (0.77–0.94) | 0.90 (0.77–0.96) | – |

\*SUV\_Max: Maximum value of SUV uptake between 2R, 2L, 4R, 4 L, 7 and aortopulmonary when evaluating per-patient, and 2R, 2L, 2R, 4 L and 7 when evaluating per-nodal-station
clearly affected, even when higher SUV_max cut off was used. On the per-patient analysis, for SUV_max > 0 we estimated specificity and positive predictive value equal to 0.45 and 0.37, respectively. When a higher cut off was used (SUV_max ≥ 5), specificity and positive predictive value increased to 0.79 and 0.54; respectively. We also found that for the same SUV cut off (≥ 5), the per-nodal station specificity was slightly higher than per-patient evaluation (0.91 vs 0.79, respectively). This finding is consistent with previous reports showing a decrease in PET-CT specificity when considering only 18F-FDG uptake as qualitative criteria for a positive exam [21–23].
Kim [23] and Lee [21] have reported two cohorts from South Korea, an endemic country for tuberculosis, with specificity of 0.84 and 0.73, respectively. Nonetheless, both studies performed a secondary analysis that only considered positive mediastinal lymph nodes with 18F-FDG uptake without associated calcification or high attenuation. This secondary analysis showed improved specificity of 0.96 and 0.89, respectively.

Additionally, dual time point PET-CT scanning for mediastinal node staging in NSCLC is still controversial. Although some studies have reported that it may be helpful in differentiating malignancy from benign processes, most studies have demonstrated significant overlap of FGD uptake patterns between benign and malignant lesions on delayed time point images [24–26]. We found a higher PET-CT’s positivity for the same SUV cut-offs, although not clinically relevant, which is consistent with previous reports [27].

Our study has some limitations. First, PET-CT has been compared against invasive staging and not the final pathologic report after surgery for all patients. Since surgery was not performed in some of the patients diagnosed with N2 disease, we did not have the pathological specimen after surgery of all patients. Second, the sensitivity found in this report is higher than the reported in the Cochrane meta-analysis, this could be explained by the number of patients included. Schmidt-Hansen [15] found a significantly higher sensitivity in studies with <100 participants compared with studies with 100 to 199 participants.

Conclusions

In conclusion, our findings are in line with the most recent publications and guidelines, which recommend that PET-CT must not be solely used as a tool to mediastinal staging, even in a region with high burden of tuberculosis. collection, analysis and interpretation of data and preparation of the manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

GW, BH, JMM, LGF, CHB, MD and CCZ were responsible for designing and conducting the study as well as interpreting study data; JALFP, MTRZ and AV performed thoracic procedures; MLZ, EHB, EV, LH, MA, CM and LCAJ were responsible for performing and interpreting PET-CT scans; VDS performed the histological examination of mediastinal lymph nodes and lung tumors; VB, RRA, GS and FZ performed data monitoring and statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was conducted in compliance with all national and international ethical standards for research with humans and for research using radiopharmaceuticals. All study procedures were approved by the Pontificia Universidade Católica do Rio Grande do Sul Institutional Ethics Committee (approval number 641.287) and patients gave written informed consent before being enrolled.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1. Latin American Cooperative Oncology Group (LACOG), Ipiranga Avenue 6681, 99A, Room 806, Porto Alegre, Brazil. 2. Medical School, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil. 3. IMED, School of Medicine, Passo Fundo, Brazil. 4. Brain Institute of Rio Grande do Sul, Porto Alegre, Brazil. 5. Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.

Received: 5 May 2018 Accepted: 19 December 2018

Published online: 03 January 2019

References

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barredor L, Bhutta ZA, et al. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 Cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524.

2. Instituto Nacional de Câncer. José Alencar Gomes. Estimativa. Incidência de Câncer no Brasil. Rio de Janeiro: INCA; 2018. http://www1.inca.gov.br/estimativa/2018/estimativa-2018.pdf.

3. Araújo LH, Baldotto C, de CJG, Katz A, Ferreira GC, Matias C, et al. Lung cancer in Brazil. J Bras Pneumol. 2018;44:55–64.

4. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEW, et al. The IASLC 18th Lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016;11:39–51.

5. Stamatis G. Staging of lung cancer: the role of noninvasive, minimally invasive and invasive techniques. Eur Respir J. 2015;46:521–31.

6. De Leyn P, Dooms C, Kuizdał J, Lardinois D, Paslick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45(5):787–98.

7. National Comprehensive Cancer Network, editor. Non-small cell lung cancer: version 3.2018. 2018. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 26 Mar 2018.
8. Vallabhajosula S. Molecular Imaging: Radiopharmaceuticals for PET and SPECT. Berlin Heidelberg: Springer-Verlag; 2009. www.springer.com/la/book/9783540767350. Accessed 14 Mar 2018

9. Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer. Chest. 2013;143:e211S–50S.

10. Cohade C, Osman M, Pannu HK, Wahl RL. Uptake in supraclavicular area fat ("USA-fat"): description on 18F-FDG PET/CT. J Nucl Med Off Publ Soc Nucl Med. 2003;44:170–6.

11. Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulteck GK. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging. 2002;29:1393–1398.

12. Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol. 2005;33:145–55 quiz 162–3.

13. Terán MD, Brock MV. Staging lymph node metastases from lung cancer in the mediastinum. J Thorac Dis. 2014;6:230–6.

14. Birim Ö, Kappetein AP, Stijnen T, Bogers AJJC. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg. 2005;79:775–82.

15. Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abraira V, Roqué i Figuls M. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev. 2014; https://doi.org/10.1002/14651858.CD009519.pub2.

16. Al-Sarraf N, Aziz R, Doddakula K, Gately K, Wilson L, McGovern E, et al. Factors causing inaccurate staging of mediastinal nodal involvement in non-small cell lung cancer patients staged by positron emission tomography. Interact Cardiovasc Thorac Surg. 2007;6:350–3.

17. Chang JM, Lee HJ, Lee H-Y, Lee JJ, Chung JK, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol. 2006;7:57–69.

18. Harkat S, Anana S, Indrajit L, Dash A. Pictorial essay: PET/CT in tuberculosis. Indian J Radiol Imaging. 2008;18:141–7.

19. World Health Organization. Global tuberculosis report 2016. 2016. http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf. Accessed 14 Mar 2018.

20. Secretaria de Vigilância em Saúde. Boletim Epidemiológico. 9th edition. Brasília - DF: Ministério da Saúde; 2015. http://portalarquivos.saude.gov.br/images/pdf/2015/marco/25/Boletim-tuberculose-2015.pdf

21. Lee JW, Kim BS, Lee DS, Chung JH, Lee MC, Kim S, et al. 18F-FDG PET/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country: consideration of lymph node calcification and distribution pattern to improve specificity. Eur J Nucl Med Mol Imaging. 2009;36:1794–802.

22. Liao C-Y, Chen J-H, Liang J-A, Yeh J-J, Kao C-H. Meta-analysis study of lymph node staging by 18 F-FDG PET/CT scan in non-small cell lung cancer: comparison of TB and non-TB endemic regions. Eur J Radiol. 2012;81:3518–23.

23. Kim YK, Lee KS, Kim B-T, Choi JY, Kim H, Kwon OJ, et al. Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients. Cancer. 2007;109:1068–77.

24. Shinozaki T, Utano K, Fuji H, Utano Y, Sasaka T, Kijima S, et al. Routine use of dual time 18F-FDG PET for staging of preoperative lung cancer: does it affect clinical management? Jpn J Radiol. 2014;32:476–81.

25. Cheng G, Torigian DA, Zhuang H, Alavi A. When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging. 2013;40:779–87.

26. Zhao M, Ma Y, Yang B, Wang Y. A meta-analysis to evaluate the diagnostic value of dual-time-point F-fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of pulmonary nodules. J Cancer Res Ther. 2016;12:304.

27. Li X, Zhang A, Xing L, Ma H, Xie P, Zhang L, et al. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study. Radiother Oncol. 2012;102:246–50.